Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Alpha-9 Oncology Inc. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution involves 1 distinct examiner and 1 distinct art unit. The company's current active docket is concentrated in a single administrative area of the USPTO. This focus is typical for specialized biotechnology firms managing a specific set of therapeutic claims.
The busiest examiner for the company is ROGERS, JAMES WILLIAM, who has 1 busiest examiner pending action. This single action constitutes the entirety of the 1 pending office action currently on record for the portfolio. Prosecution strategy for these biotechnology claims is therefore dependent on the specific requirements and feedback of ROGERS, JAMES WILLIAM. There are no other examiners or 1 distinct art units involved in the current workload, which simplifies the coordination of the company's legal efforts. Practitioners should focus on building a consistent dialogue with the examiner to resolve the active matter. Success in the Biotechnology & Pharmaceuticals area for this portfolio is currently tied to this specific examination track.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267987 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ROGERS, JAMES WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267987 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ROGERS, JAMES WILLIAM | 1618 | §103 | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlpha-9 Oncology Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
James William Rogers has the most, with 1 of Alpha-9 Oncology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
